In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May

18.2 Managing Side Effects at Home Patients can mitigate mild side effects through practical measures: Consume smaller, frequent meals Avoid high-fat foods Maintain hydration 18.3 Adherence to Weekly Injection Schedule Consistency is paramount
Monitor Your Energy: Keep a journal of how you feel, noting changes in fatigue, skin clarity, and digestion
R., Claude, A
Understanding IBD Medications and Side Effects
Yes, pairing testosterone or TRT with a GLP-1 agonist such as semaglutide or tirzepatide is not only feasible but also advantageous for your health and fitness objectives